Number of the records: 1
Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism
- 1.
SYSNO ASEP 0393023 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism Author(s) Weber, Jan (UOCHB-X) RID, ORCID
Vazquez, A. C. (US)
Winner, D. (US)
Gibson, R. M. (US)
Rhea, A. M. (US)
Rose, J. D. (US)
Wylie, D. (US)
Henry, K. (US)
Wright, A. (US)
King, K. (US)
Archer, J. (GB)
Poveda, E. (ES)
Soriano, V. (ES)
Robertson, D. L. (GB)
Olivo, P. D. (US)
Arts, E. J. (US)
Quinones-Mateu, M. E. (US)Number of authors 17 Source Title Journal of Clinical Microbiology - ISSN 0095-1137
Roč. 51, č. 5 (2013), s. 1517-1527Number of pages 11 s. Language eng - English Country US - United States Keywords HIV tropism ; phenotypic assay ; genotypic prediction ; disease progression ; CCR5 antagonists ; naive patients Subject RIV EE - Microbiology, Virology Institutional support UOCHB-X - RVO:61388963 UT WOS 000317602100027 EID SCOPUS 84876750679 DOI 10.1128/JCM.00092-13 Annotation CCR5 antagonists are a powerful new class of antiretroviral drugs that require a companion assay to evaluate the presence of CXCR4-tropic viruses prior to use in human immunodeficiency virus (HIV)-infected individuals. In this study, we have developed, characterized, verified, and prevalidated a novel phenotypic test to determine HIV-1 coreceptor tropism (VERITROP) based on a sensitive cell-to-cell fusion assay. The env-expressing vectors were used in a cell-to-cell fusion assay to determine the presence of R5 and/or non-R5 HIV-1 variants within the viral population. Results were compared with (i) the original version of Trofile, (ii) population sequencing, and (iii) 454 pyrosequencing, with the genotypic data analyzed using several bioinformatics tools, i. e., the 11/24/25 rule, Geno2Pheno, and webPSSM. VERITROP consistently detected minority non-R5 variants from clinical specimens, with an analytical sensitivity of 0.3%, with viral loads of >= 1,000 copies/ml, and from B and non-B subtypes. In a pilot study, a 73.7% (56/76) concordance was observed with the original Trofile assay, with 19 of the 20 discordant results corresponding to non-R5 variants detected using VERITROP and not by the original Trofile assay. The degree of concordance of VERITROP and Trofile with population and deep sequencing results depended on the algorithm used to determine HIV-1 coreceptor tropism. Overall, VERITROP showed better concordance with deep sequencing/Geno2Pheno at a 0.3% detection threshold (67%), whereas Trofile matched better with population sequencing (79%). However, 454 sequencing using Geno2Pheno at a 10% FPR and 0.3% threshold and VERITROP more accurately predicted the success of a maraviroc-based regimen. In conclusion, VERITROP may promote the development of new HIV coreceptor antagonists and aid in the treatment and management of HIV-infected individuals prior to and/or during treatment with this class of drugs. Workplace Institute of Organic Chemistry and Biochemistry Contact asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Viktorie Chládková, Tel.: 232 002 434 Year of Publishing 2014
Number of the records: 1